Shattuck Labs, Inc. (STTK) Friday announced additional positive interim data from the Phase 1B study of SL-172154 in combination with Azacitidine (AZA) in frontline higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML) patients.
Objective response rate (ORR), percentage of people who have a partial response or complete response to the treatment, was 67 percent in HR-MDS patients, primarily with TP53 mutations, who were treated with SL-172154 plus AZA. 42 percent patients achieved a complete remission (CR) with 3.6 months as the median time to CR.
ORR was 43 percent in frontline TP53m AML patients, and 29 percent of patients achieved a CR.
Further, SL-172154 demonstrated a manageable interim safety profile in combination with AZA
"Enrollment is now underway for our randomized, controlled expansion cohort in frontline HR-MDS patients, and we expect to engage in regulatory discussions later this year regarding the registrational strategy for SL-172154," said Lini Pandite, Chief Medical Officer of Shattuck.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.